Brought to you by 
Servier gets an option to develop and sell GeNeuro’s multiple sclerosis candidate
02 Feb 2023
Executive Summary
Servier SA took an option to join in on the development of GeNeuro SA’s GNbAC1, a Phase II monoclonal antibody aimed at a causal factor of multiple sclerosis.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Servier gets an option to develop and sell GeNeuro’s multiple sclerosis candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice